Abstract
Abstract Chronic inflammation has been implicated in the pathogenesis of colorectal cancer. C-reactive protein (CRP), a biomarker of systemic inflammation, has been investigated in various populations for its association with colorectal cancer risk, but results have been inconsistent. We examined pre-diagnostic circulating levels of CRP with colorectal cancer risk among 288 colorectal cancer cases and 576 frequency-matched controls nested within the Shanghai Men's Health Study (2002-2006), a population-based cohort study of 61,483 men. Baseline plasma CRP levels were 47% higher among men who subsequently developed colorectal cancer than among those who remained free of the disease (1.12 μg/ml vs. 0.76 μg/ml; P<0.001). Multivariate analyses showed a dose-dependent relationship between CRP and colorectal cancer risk (P-trend=0.001); men in the highest tertile with CRP >1.19 μg/ml had 1.88-fold (95%CI: 1.24-2.86) increased odds of developing colorectal cancer compared with men in the lowest tertile with CRP <0.45 μg/ml. The association was observed for both colon and rectal cancers, became stronger after excluding subjects who took any antibiotics during past 7 days, and was restricted to cancer cases diagnosed within 4 years of blood collection (ORs for the highest tertile being 3.28 (95%CI: 1.28-8.37), 3.68 (95%CI: 1.62-8.38), and 1.05 (95%CI: 056-1.97), respectively for cases diagnosed within 2, 2-4 and 4 years after blood draw). The findings from our study suggest that circulating CRP level is positively associated with colorectal cancer risk in Chinese men, and this association, at least in part, is explained by inflammation related to cancerous or precancerous processes. Citation Format: Jie Wu, Qiuyin Cai, Honglan Li, Hui Cai, Jing Gao, Gong Yang, Wei Zheng, Yong-Bing Xiang, Xiao-ou Shu. Circulating C-reactive protein and colorectal cancer risk: a report from the Shanghai Men's Health Study. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 102. doi:10.1158/1538-7445.AM2013-102
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
